News Center

News Center

The latest clinical updates and product development news from Progenity.

We announced results from three studies that represent potential breakthrough systems for diagnosing, treating, and monitoring digestive diseases through ingestible technologies.

Progenity, Inc., a privately held biotechnology company developing precision medicine solutions across genomic/epigenomic, proteomic, and microbiomic diagnostic and therapeutic platforms, this week announced three upcoming poster presentations.

Highlighting the Resura® Prenatal Test

Progenity also announces improvements to its Innatal® noninvasive prenatal test (NIPT), demonstrating market-leading sensitivity and specificity across all common chromosomal aneuploidies.

Zoom in from full chromosome to single nucleotide with a new application for cell-free DNA (cfDNA) technology. Expand your patients’ prenatal options with the Resura™ Prenatal Test.

Presenting at the BTIG, Raymond James, and Cowen health care conferences.

Company focused on diagnostic and therapeutic precision medicine solutions in prenatal and perinatal healthcare, oncology, and gastroenterology.

That's how many clear and actionable answers have been provided to patients with Progenity’s genetic testing since the launch of our next-generation sequencing platform in 2014.

Know more. Learn how we have improved our Innatal® Prenatal Screen.

In March 2017, the American College of Obstetricians and Gynecologists (ACOG) issued two new Committee Opinions regarding carrier testing for patients who are pregnant or considering pregnancy.